erlotinib hydrochloride has been researched along with Intracranial Aneurysm in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hou, W; Huang, Q; Liu, J; Luo, Y; Tang, H; Wang, C; Zhang, Z; Zhao, R | 1 |
1 other study(ies) available for erlotinib hydrochloride and Intracranial Aneurysm
| Article | Year |
|---|---|
Pharmacological inhibition of epidermal growth factor receptor attenuates intracranial aneurysm formation by modulating the phenotype of vascular smooth muscle cells.
Topics: Animals; Cell Movement; Cell Proliferation; Cells, Cultured; Endothelial Cells; Endothelium, Vascular; ErbB Receptors; Erlotinib Hydrochloride; Humans; Intracranial Aneurysm; Male; Muscle, Smooth, Vascular; Phenotype; Protein Kinase Inhibitors; Rats; Tumor Necrosis Factor-alpha | 2022 |